Frontline Treatment of Acute Myeloid Leukemia

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.

Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.

Experts explain the goals of treatment for acute myeloid leukemia and the challenges presented.

Eytan Stein, MD, provides an overview of the frontline treatment options currently available for acute myeloid leukemia.

Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction therapy.

Eytan Stein, MD, reviews the available treatment options for patients with secondary AML or AML with myelodysplasia-related changes.

Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.

Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.

Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.